EPS Creative Health Technology Group Valuation
Is 3860 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 3860 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 3860's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 3860's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3860?
Other financial metrics that can be useful for relative valuation.
| What is 3860's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | HK$313.31m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | -24x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 3860's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.9x | ||
1247 Miko International Holdings | 1.7x | n/a | HK$350.6m |
1466 Affluent Partners Holdings | 6.7x | n/a | HK$360.6m |
1657 SG Group Holdings | 2.4x | n/a | HK$291.2m |
643 Carry Wealth Holdings | 0.7x | n/a | HK$422.9m |
3860 EPS Creative Health Technology Group | 0.4x | n/a | HK$313.3m |
Price-To-Sales vs Peers: 3860 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.9x).
Price to Earnings Ratio vs Industry
How does 3860's PE Ratio compare vs other companies in the HK Luxury Industry?
Price-To-Sales vs Industry: 3860 is good value based on its Price-To-Sales Ratio (0.4x) compared to the Hong Kong Luxury industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is 3860's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 3860's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.